Sickle Cell Disease
An inherited hemoglobin disorder that causes red blood cells to become rigid and sickle-shaped, leading to pain crises, anemia, and progressive organ damage.
- Specialist hematology review
- Access to gene therapy options
- Pain crisis & complication management
- Inheritance
- Autosomal Recessive (HBB gene, HbS)
- Most Common In
- African, Mediterranean, Middle Eastern, South Asian ancestry
- Clinical Hallmark
- Recurrent Vaso-Occlusive Pain Crises
- Advanced Therapies
- Gene Therapy, Crizanlizumab, Voxelotor, Transplant
Condition Overview
Sickle cell disease is a group of inherited disorders caused by a mutation in the HBB gene, which produces an abnormal form of hemoglobin called hemoglobin S (HbS). Under low-oxygen conditions, HbS causes red blood cells to stiffen into a rigid, sickle shape instead of staying flexible and round.
These misshapen cells can block small blood vessels, causing episodes of severe pain known as vaso-occlusive crises, and they break down faster than normal red cells, leading to chronic anemia. Over time, repeated vessel blockage and inflammation can damage organs including the spleen, kidneys, lungs, and brain.
SCD is present from birth and affects people throughout life, though severity and complication patterns vary by genotype and individual factors. Comprehensive, lifelong care โ including preventive therapies and prompt management of crises โ substantially improves quality of life and long-term outcomes.
Types and Subtypes
Sickle cell disease subtypes are defined by which hemoglobin genes a person inherits, which influences disease severity.
Symptoms and Signs
Symptoms can begin in infancy and range from chronic, low-level effects of anemia to sudden, severe pain crises.
Causes and Risk Factors
Sickle cell disease is caused entirely by inherited gene mutations affecting hemoglobin; it cannot be caused or prevented by lifestyle factors.
Diagnosis and Investigations
Diagnosis relies on identifying abnormal hemoglobin and confirming the specific genotype, often beginning with newborn screening.
Disease Severity Classification
SCD does not use a cancer-style staging system; severity is instead classified by genotype and clinical complication burden, which guides preventive treatment intensity.
Standard Treatment Options
Management combines preventive therapies that reduce complication frequency with prompt treatment of acute crises.
Advanced and Emerging Treatment Options
In recent years, targeted biologic therapies and gene-based treatments have expanded options for patients with frequent crises or severe disease.
Gene Therapy
Gene therapy (gene addition or gene editing approaches)
Approved gene therapies modify a patient's own blood stem cells to reduce sickling, offering a potentially durable treatment for eligible patients with severe disease.
Cellular Therapy
Allogeneic hematopoietic stem cell transplant
Can be curative by replacing the blood-forming system with donor cells from a matched donor, generally considered for select severe cases.
Targeted Therapy
Crizanlizumab
A monoclonal antibody that targets P-selectin to reduce vaso-occlusive crisis frequency.
Targeted Therapy
Voxelotor
An oral agent that increases hemoglobin's affinity for oxygen, reducing sickling and improving anemia in some patients.
Biomarkers and Precision Medicine
Several laboratory and genetic markers help guide treatment intensity and monitor for complications in sickle cell disease.
When a Second Opinion May Be Important
Given the range of available therapies, specialist review can help match treatment intensity to individual risk and goals.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in sickle cell disease have improved substantially with newborn screening, preventive care, and an expanding range of disease-modifying and curative therapies, though individual course depends on genotype and complication history.
Supportive Care and Living With Sickle Cell Disease
Ongoing supportive measures help reduce complications and improve day-to-day quality of life.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with sickle cell disease access specialist hematology review, second opinions on disease-modifying therapy, and coordination for gene therapy or transplant evaluation.
Get a free case reviewFrequently Asked Questions
It is an inherited blood disorder in which abnormal hemoglobin causes red blood cells to become rigid and sickle-shaped, leading to pain crises, anemia, and organ damage over time.
Early signs often include painful swelling of the hands and feet in infants, jaundice, fatigue from anemia, and recurrent pain episodes.
No. Sickle cell trait means a person carries one copy of the sickle gene and is generally healthy, while sickle cell disease involves two affected hemoglobin genes and causes clinical symptoms.
Hematopoietic stem cell transplant and newer gene therapies can be curative for eligible patients, though most people are managed long-term with preventive and disease-modifying treatments.
Common triggers include dehydration, infection, extreme temperatures, high altitude, and physical stress, although crises can also occur without an identifiable trigger.
Hydroxyurea is a disease-modifying medication that increases fetal hemoglobin and reduces the frequency of pain crises and acute chest syndrome.
Approved gene therapies modify a patient's own blood stem cells outside the body to reduce sickling, then return them through a transplant-like procedure.
Yes, it follows an autosomal recessive pattern, requiring an affected hemoglobin gene from each parent.
Fever, chest pain with breathing difficulty, sudden weakness or speech changes, and prolonged painful erection all require urgent medical evaluation.
Yes. CancerFax can help coordinate medical report review, connect you with hematology specialists for a second opinion, and support access to gene therapy or transplant evaluation, including cross-border coordination where needed.
Get Expert Guidance for Sickle Cell Disease
Share your reports with our team to explore specialist review, treatment options, and second opinion support.